PDF(Pubmed)
Abstract：
The potential role of circulating microRNAs (miRNAs) as biomarkers in breast cancer (BC) management has been widely reported. However, the numerous discrepancies between studies in this regard hinders the implementation of circulating miRNAs in routine clinical practice. In the context of BC patients undergoing neoadjuvant chemotherapy (NAC), the possibility of predicting NAC response may lead to prognostic improvements by individualizing post-neoadjuvant therapy. In this context, the present meta-analysis aims to clarify circulating miRNAs\' predictive role with respect to NAC response among BC patients. We conducted a comprehensive literature search on five medical databases until 16 February 2023. We pooled the effect sizes of each study by applying a random-effects model. Cochran\'s Q test (p-level of significance set at 0.05) scores and I2 values were assessed to determine between-study heterogeneity. The PROBAST (Prediction Model Risk of Bias Assessment Tool) tool was used to evaluate the selected studies\' risk of bias. Overall, our findings support the hypothesis that circulating miRNAs, specifically miR-21-5p and miR-155-5p, may act as predictive biomarkers in the neoadjuvant setting among BC patients. However, due to the limited number of studies included in this meta-analysis and the high degrees of clinical and statistical heterogeneity, further research is required to confirm the predictive power of circulating miR-21-5p and miR-155-5p.
摘要：
循环微小RNA（miRNA）作为生物标志物在乳腺癌（BC）管理中的潜在作用已被广泛报道。然而,在这方面,研究之间的大量差异阻碍了循环miRNA在常规临床实践中的应用.在接受新辅助化疗（NAC）的BC患者中，通过对新辅助治疗后的个体化治疗,预测NAC反应的可能性可能导致预后改善.在这种情况下，本荟萃分析旨在阐明循环miRNA对BC患者NAC反应的预测作用.我们对5个医学数据库进行了全面的文献检索，直至2023年2月16日。我们通过应用随机效应模型汇总了每项研究的效应大小。评估Cochran的Q检验(P-显著性水平设定为0.05)评分和I2值以确定研究之间的异质性。使用PROBAST（预测模型偏差风险评估工具）工具评估选定研究的偏差风险。总的来说,我们的发现支持循环miRNA的假设，特别是miR-21-5p和miR-155-5p，可能在BC患者的新辅助治疗中充当预测性生物标志物。然而,由于本荟萃分析中包含的研究数量有限，以及高度的临床和统计异质性，需要进一步的研究来确认循环miR-21-5p和miR-155-5p的预测能力。
